Details of the Drug

General Information of Drug (ID: DM6Q7U4)

Drug Name
Lenalidomide
Synonyms
Revamid; Revimid; Revlimid; Celgene brand of lenalidomide; Lenalidomide [USAN]; CC 5013; CC5013; CDC 501; IMiD3; IMiD3cpd; ALBB-015321; CC-5013; CDC-501; CDC-5013; ENMD-0997; IMID-5013; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013; Lenalidomide (USAN/INN); CC-5013, Revlimid, Lenalidomide; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenalidomide (Immunomodulator)
Indication
Disease Entry ICD 11 Status REF
Adult T-cell leukemia/lymphoma N.A. Approved [1]
Advanced cancer 2A00-2F9Z Approved [1]
Complex regional pain syndrome type 1 N.A. Approved [1]
Hepatosplenic T-cell lymphoma N.A. Approved [1]
Large granular lymphocytic leukemia 2A90.1 Approved [1]
Leukemia N.A. Approved [1]
MALT lymphoma N.A. Approved [1]
Multiple myeloma 2A83 Approved [2]
Nodal marginal zone lymphoma 2A85.0 Approved [1]
Pain MG30-MG3Z Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [1]
Prolymphocytic leukaemia 2A82.1 Approved [1]
Recurrent adult burkitt lymphoma 2A85.6 Approved [1]
Small intestine lymphoma N.A. Approved [1]
Splenic marginal zone lymphoma N.A. Approved [1]
Testicular lymphoma N.A. Approved [1]
Urinary bladder neoplasm N.A. Approved [1]
Waldenstrom macroglobulinemia 2A85.4 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Colon cancer 2B90.Z Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 259.26
Logarithm of the Partition Coefficient (xlogp) -0.5
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [4]
Elimination
66% of drug is excreted from urine in the unchanged form [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.375 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.00045 mg/mL [4]
Chemical Identifiers
Formula
C13H13N3O3
IUPAC Name
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
Canonical SMILES
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
InChI
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChIKey
GOTYRUGSSMKFNF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
216326
ChEBI ID
CHEBI:63791
CAS Number
191732-72-6
DrugBank ID
DB00480
TTD ID
D0Q5NX
VARIDT ID
DR00261
ACDINA ID
D00353
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Angiopoietin-1 receptor (TEK) OT78YN57 TIE2_HUMAN Gene/Protein Processing [8]
DNA damage-binding protein 1 (DDB1) OTTR2L3Z DDB1_HUMAN Protein Interaction/Cellular Processes [9]
Fibroblast growth factor receptor 1 (FGFR1) OT4GLCXW FGFR1_HUMAN Gene/Protein Processing [10]
Fibroblast growth factor receptor 2 (FGFR2) OTLOPACK FGFR2_HUMAN Gene/Protein Processing [10]
Fibroblast growth factor receptor 3 (FGFR3) OTSAXDIL FGFR3_HUMAN Gene/Protein Processing [10]
Interleukin-1 receptor type 1 (IL1R1) OTTU8959 IL1R1_HUMAN Gene/Protein Processing [8]
Interleukin-6 receptor subunit beta (IL6ST) OT1N9C70 IL6RB_HUMAN Gene/Protein Processing [8]
Protein cereblon (CRBN) OTXH9MDC CRBN_HUMAN Drug Response [11]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Gene/Protein Processing [8]
Sal-like protein 4 (SALL4) OTC08PR5 SALL4_HUMAN Protein Interaction/Cellular Processes [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Adult T-cell leukemia/lymphoma
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 8.64E-01 -0.06 -0.16
P-glycoprotein 1 (ABCB1) DTP P-GP 9.83E-01 3.92E-01 4.44E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lenalidomide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Decreased clearance of Lenalidomide due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [13]
Arn-509 DMT81LZ Moderate Accelerated clearance of Lenalidomide due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [13]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [14]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Lenalidomide and Roflumilast. Asthma [CA23] [13]
Erdafitinib DMI782S Moderate Decreased clearance of Lenalidomide due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [15]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Lenalidomide and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [16]
Tucatinib DMBESUA Moderate Decreased clearance of Lenalidomide due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [17]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Cannabidiol. Epileptic encephalopathy [8A62] [13]
GS-5885 DMSL3DX Moderate Decreased clearance of Lenalidomide due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [18]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Brentuximab vedotin. Hodgkin lymphoma [2B30] [19]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [20]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Lenalidomide and Mipomersen. Hyper-lipoproteinaemia [5C80] [21]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Lenalidomide and Teriflunomide. Hyper-lipoproteinaemia [5C80] [22]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Methotrexate. Leukaemia [2A60-2B33] [13]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Lenalidomide and Denosumab. Low bone mass disorder [FB83] [23]
Capmatinib DMYCXKL Moderate Decreased clearance of Lenalidomide due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [24]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [25]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Idelalisib. Mature B-cell leukaemia [2A82] [26]
Lasmiditan DMXLVDT Moderate Decreased clearance of Lenalidomide due to the transporter inhibition by Lasmiditan. Migraine [8A80] [27]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Lenalidomide and Siponimod. Multiple sclerosis [8A40] [28]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Lenalidomide and Fingolimod. Multiple sclerosis [8A40] [29]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Lenalidomide and Ocrelizumab. Multiple sclerosis [8A40] [30]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Lenalidomide and Ozanimod. Multiple sclerosis [8A40] [13]
Nilotinib DM7HXWT Moderate Decreased clearance of Lenalidomide due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [31]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Lenalidomide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [32]
Enzalutamide DMGL19D Moderate Accelerated clearance of Lenalidomide due to the transporter induction by Enzalutamide. Prostate cancer [2C82] [33]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Lenalidomide and Canakinumab. Rheumatoid arthritis [FA20] [34]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Lenalidomide and Rilonacept. Rheumatoid arthritis [FA20] [34]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Lenalidomide and Golimumab. Rheumatoid arthritis [FA20] [35]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Lenalidomide and Leflunomide. Rheumatoid arthritis [FA20] [22]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Lenalidomide when combined with Anthrax vaccine. Sepsis [1G40-1G41] [36]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [13]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Lenalidomide and Naltrexone. Substance abuse [6C40] [37]
Fostamatinib DM6AUHV Moderate Decreased clearance of Lenalidomide due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [38]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Lenalidomide and Azathioprine. Transplant rejection [NE84] [28]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Lenalidomide and Ganciclovir. Virus infection [1A24-1D9Z] [28]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Lenalidomide and Valganciclovir. Virus infection [1A24-1D9Z] [28]
⏷ Show the Full List of 37 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lenalidomide 10 mg capsule 10 mg Oral Capsule Oral
Lenalidomide 15 mg capsule 15 mg Oral Capsule Oral
Lenalidomide 2.5 mg capsule 2.5 mg Oral Capsule Oral
Lenalidomide 20 mg capsule 20 mg Oral Capsule Oral
Lenalidomide 25 mg capsule 25 mg Oral Capsule Oral
Lenalidomide 5 mg capsule 5 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Lenalidomide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7331).
3 Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial (GETAFE)
4 BDDCS applied to over 900 drugs
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
7 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480)
8 Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005 Apr 15;105(8):3286-94. doi: 10.1182/blood-2004-06-2101. Epub 2004 Dec 23.
9 Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014 Sep;21(9):803-9. doi: 10.1038/nsmb.2874. Epub 2014 Aug 10.
10 Thalidomide and Its Analogs Differentially Target Fibroblast Growth Factor Receptors: Thalidomide Suppresses FGFR Gene Expression while Pomalidomide Dampens FGFR2 Activity. Chem Res Toxicol. 2019 Apr 15;32(4):589-602. doi: 10.1021/acs.chemrestox.8b00286. Epub 2019 Mar 15.
11 A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples. Appl Immunohistochem Mol Morphol. 2016 Nov/Dec;24(10):695-702. doi: 10.1097/PAI.0000000000000246.
12 Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018 Aug 1;7:e38430. doi: 10.7554/eLife.38430.
13 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
15 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
16 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
17 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
18 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
19 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
20 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
21 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
22 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
23 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
24 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
25 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
26 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
27 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
28 Cerner Multum, Inc. "Australian Product Information.".
29 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
30 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
31 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
32 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
33 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
34 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
35 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
36 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
37 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
38 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.